Form 4: Enliven Therapeutics CFO Benjamin Hohl Executes Option and Sells Shares Under 10b5-1 Plan

Benjamin Hohl, CFO of Enliven Therapeutics, exercised stock options and sold shares of common stock under a pre-arranged 10b5-1 trading plan.

Summary

• On August 27, 2024, Benjamin Hohl, the Chief Financial Officer of Enliven Therapeutics, Inc. (ELVN), exercised stock options to acquire 4,250 shares of common stock at a price of $2.48 per share.
• Simultaneously, Hohl sold 4,250 shares of common stock at a weighted average price of $22.5369, with individual sales prices ranging from $22.02 to $22.94.
• These transactions were executed under a Rule 10b5-1 trading plan adopted by Hohl on June 26, 2023.
• Following these transactions, Hohl directly owns 0 shares of common stock and 199,129 derivative securities (stock options).

Sentiment

Score: 5

Explanation: The document is a standard regulatory filing detailing insider transactions. It doesn't inherently convey positive or negative sentiment, but rather provides factual information about stock option exercises and sales.

Future Outlook

The document does not contain any specific forward-looking statements or guidance.

Industry Context

Form 4 filings are a routine part of the regulatory landscape for publicly traded companies. They provide transparency into the transactions of company insiders, allowing investors to track potential shifts in ownership and sentiment. The use of a 10b5-1 trading plan suggests that the insider's transactions were pre-planned and not based on any material non-public information.

Comparison to Industry Standards

• Insider transactions are common across publicly listed companies, and the reporting requirements are standardized by the SEC.
• The use of 10b5-1 trading plans is a widely accepted practice to avoid accusations of insider trading, aligning with industry best practices for compliance and transparency.
• Comparable companies in the biotechnology sector, such as Amgen, Gilead Sciences, and Biogen, also see regular Form 4 filings from their executives and directors.

Stakeholder Impact

• The transactions may have a minor impact on shareholders by slightly increasing the supply of shares in the market.
• The execution of the 10b5-1 trading plan ensures transparency and reduces the risk of accusations of insider trading, which benefits all stakeholders.

Key Dates